David Chang Net Worth

The estimated Net Worth of David D Chang is at least $22.2 Million dollars as of 15 March 2022. David Chang owns over 23,648 units of Allogene Therapeutics Inc stock worth over $6,662,887 and over the last 8 years he sold ALLO stock worth over $4,304,030. In addition, he makes $11,192,100 as President, Chief Executive Officer, Co-Founder, and Director at Allogene Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

David Chang ALLO stock SEC Form 4 insiders trading

David has made over 11 trades of the Allogene Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 23,648 units of ALLO stock worth $180,907 on 15 March 2022.

The largest trade he's ever made was exercising 60,000 units of Allogene Therapeutics Inc stock on 1 March 2017 worth over $413,400. On average, David trades about 7,562 units every 58 days since 2016. As of 15 March 2022 he still owns at least 2,289,652 units of Allogene Therapeutics Inc stock.

You can see the complete history of David Chang stock trades at the bottom of the page.

David Chang biography

Dr. David Chang, M.D. Ph.D., serves as President, Chief Executive Officer, Co-Founder, Director of the Company. Prior to joining us, Dr. Chang served as the Chief Medical Officer and Executive Vice President, Research and Development of Kite from June 2014 until March 2018. Dr. Chang previously held senior positions at Amgen Inc., a biopharmaceutical company, including Vice President, Global Development from July 2006 to May 2014, Senior Director, Oncology-Therapeutics from July 2005 to June 2006 and Director, Medical Sciences from December 2002 to June 2005. Prior to that, he was an Associate Professor at the University of California, Los Angeles School of Medicine. He has also served as a Venture Partner of Vida Ventures, LLC since November 2017, and Two River Consulting, LLC since October 2017. Dr. Chang obtained a B.S. in Biology from the Massachusetts Institute of Technology and an M.D. and Ph.D. from Stanford University.

What is the salary of David Chang?

As the President, Chief Executive Officer, Co-Founder, and Director of Allogene Therapeutics Inc, the total compensation of David Chang at Allogene Therapeutics Inc is $11,192,100. There are no executives at Allogene Therapeutics Inc getting paid more.

How old is David Chang?

David Chang is 60, he's been the President, Chief Executive Officer, Co-Founder, and Director of Allogene Therapeutics Inc since 2018. There are 6 older and 14 younger executives at Allogene Therapeutics Inc. The oldest executive at Allogene Therapeutics Inc is David Bonderman, 77, who is the Lead Independent Director.

Insiders trading at Allogene Therapeutics Inc

Over the last 6 years, insiders at Allogene Therapeutics Inc have traded over $137,494,387 worth of Allogene Therapeutics Inc stock and bought 2,891,304 units worth $29,333,135 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Arie Belldegrun, and Inc Pfizer. On average, Allogene Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $286,894. The most recent stock trade was executed by Deborah M. Messemer on 18 June 2024, trading 18,641 units of ALLO stock currently worth $42,501.

What does Allogene Therapeutics Inc do?

allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le

Complete history of David Chang stock trades at Allogene Therapeutics Inc

Allogene Therapeutics Inc executives and stock owners

Allogene Therapeutics Inc executives and other stock owners filed with the SEC include:

• David Chang,
  President, Chief Executive Officer, Co-Founder, Director
• Rafael Amado,
  Executive Vice President - Research and Development, Chief Medical Officer
• Arie Belldegrun,
  Executive Chairman of the Board
• Eric Schmidt,
  Chief Financial Officer
• Alison Moore,
  Chief Technical Officer
• Dr. David D. Chang M.D., Ph.D.,
  Co-Founder, Pres, CEO & Director
• Joshua Kazam,
  Co-Founder, Director
• Dr. Rafael G. Amado M.D.,
  Exec. VP of R&D
• Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D.,
  Co-Founder & Exec. Chairman
• Dr. Arie S. Belldegrun F.A.C.S., M.D., FACS,
  Co-Founder & Exec. Chairman
• Dr. Rafael G. Amado,
  Chief Medical Officer and Exec. VP of R&D
• Dr. Alison Moore Ph.D.,
  Chief Technical Officer
• Dr. Eric Thomas Schmidt Ph.D.,
  Chief Financial Officer
• Veer Bhavnagri,
  Gen. Counsel & Compliance Officer
• Franz Humer,
  Independent Director
• Deborah Messemer,
  Independent Director
• Owen Witte,
  Independent Director
• Joshua A. Kazam,
  Co-Founder & Director
• Veer Bhavnagri,
  Chief Compliance Officer, General Counsel
• Todd Sisitsky,
  Independent Director
• John DeYoung,
  Independent Director
• David Bonderman,
  Lead Independent Director
• Stephen Cheng,
  Chief Information Officer
• David M. Tanen J.D.,
  Sec.
• Christine Cassiano,
  Chief Communications Officer
• Barbra Sasu,
  Chief Scientific Officer
• Timothy L. Moore,
  Chief Technical Officer
• Yinlin Jack Chen,
  SVP, Finance
• Inc Pfizer,
  10% owner
• Earl Martin Douglas,
  SVP, General Counsel
• Elizabeth A. Barrett,
  
• Vicki L Sato,
  
• Equity Holdings 2 B.V. Pf,
  10% owner
• Stephen Mayo,
  
• Zachary Roberts,
  EVP of R&D
• Lillian Smith,
  VP, Corporate Counsel
• Geoffrey M. Parker,
  CHIEF FINANCIAL OFFICER